Introduction
============

Familial Mediterranean fever (FMF) is one the most common autoinflammatory disease (AID). Pathogenomic relevant mutations in the MEFV gene show autosomal recessive inheritance, but co-dominant mutations have been described.

Objectives
==========

We aimed to evaluate correlations between ethnic origin, phenotype and genotype for FMF patients in the German AID-Net-registry.

Methods
=======

We used two common scoring systems modified for children (Mor et al., Pras et al.) to assess disease severity in 243 FMF patients of the AID-Net-registry. For the four most frequent mutations, we tested for a correlation of the genotype with the phenotype, mean CRP and ethnic origin, respectively. Furthermore, we evaluated the applicability of the two severity scores for children.

Results
=======

Among the 243 patients, we detected a total of 433 pyrin mutations and 22 different sequence variants, including one new mutation (p.Gly488Asp). The four most frequent alterations were p.Met694Val (55%, n=238), p.Met680lle (12%, n=52), p.Val726Ala (10%, n=44) and p.Glu148Gln (8%, n=34). Ethnic origin could be determined in 224 cases; the prevailing ancestry was Turkish (83%, n=185), 8% (n=18) were Lebanese. P.Met694Val in homozygous form (n=74; 30.5%) was correlated with a more severe disease activity, based on the score by Mor, as well as with a higher mean CRP (74 mg/l, n=60, 31 mg/l, n=59) compared to patients without this mutation (p=0.01 and p\<0.01, respectively). The score suggested by Pras did not yield a significant genotype-phenotype correlation; indeed, the two scoring systems were inconsistent with each other (κ\<0.07). Although a typical distribution of mutations in different ethnic populations was obvious, this trend was not statistically significant, probably due to the divergent number of cases.

Conclusion
==========

The homozygous p.Met694Val substitution was associated with a more severe disease activity. There was no origin-genotype correlation in this FMF population. The well-known severity scores for children (Mor, Pras) are inconsistent.
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